RELATIONSHIPS HOMOCYSTEINE AND ARTERIAL STIFFNESS IN PATIENTS WITH H-TYPE ARTERIAL HYPERTENSION

Abstract

Objective: The aim of our study was to evaluate the prevalence of hyperhomocystinemia in patients with mild to moderate hypertension, to investigate the relationship between hyperhomocystinemia with arterial stiffness. Design and method: In the study was included 40 patients with mild and moderate hypertension. Performed measurements of office SBP, DBP, (24AMBP), determination of pulse wave velocity in arteries of elastic (PWVel) and muscular (PWVm) types, central SBP, biochemical blood test with homocysteine. Homocysteine > = 10 μmol / l), the called H-type hypertension. Patients treatment mono-, dual or triple combination (telmisartane, amlodipine, hydrochlortiazide). All tests was performed before and after 6 month therapy. Statistical results was performed using the software IBM Statistics SPSS 21. Results: The mean age of patients was 55.85 ± 2.09 (26 – 74) years. The average body weight was 87.3 ± 2.77 kg. The average BMI is 29.41 ± 0.63 kg / m2. The average office SBP/DBP at the beginning of the study were 155.88 ± 1.63/92.60 ± 1.43 mm Hg. The average office heart rate 71.40 ± 1.29 beats / min. Mean 24 SBP/DBP monitoring were 139.37 ± 1.49/82.47 ± 1.84 mm Hg. The average daily heart rate 71.38 ± 1.32 beats / min. We found that at the beginning of the study, 75% (30 patients with mild and moderate hypertension) had elevated of blood homocysteine more than 10 μmol / l). PWV was associated after regression analyses with homocysteine. PWV el after treatment (r = 0,307, p = 0,001). PWV m after treatment (r = - 0,733, p = 0,001). Office SBP after treatment (r = 0,423, p < 0,001). Office DBP after treatment (r = - 0,675, p = 0,001). CKD-EPI after treatment (r = - 0,342, p = 0,005). BMI after treatment (r = 0,227, p = 0,026). Creatinine before treatment (r = -0,411, p = 0,003). Creatinine after treatment (r = 0,572, p = 0,011). Conclusions: Homocysteine associated with vascular stiffness, independent of the blood pressure reduction during treatment.